Hypera S.A. (BVMF:HYPE3)

Brazil flag Brazil · Delayed Price · Currency is BRL
25.35
-2.22 (-8.05%)
At close: Dec 5, 2025
29.20%
Market Cap 16.05B
Revenue (ttm) 6.97B
Net Income (ttm) 823.94M
Shares Out 632.94M
EPS (ttm) 1.29
PE Ratio 19.58
Forward PE 8.69
Dividend 1.17 (4.24%)
Ex-Dividend Date Sep 29, 2025
Volume 4,221,300
Average Volume 2,130,935
Open 27.30
Previous Close 27.57
Day's Range 25.35 - 27.79
52-Week Range 16.62 - 28.87
Beta 0.25
RSI 73.37
Earnings Date Feb 20, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]

Sector Healthcare
Founded 1999
Employees 10,481
Stock Exchange Brazil Stock Exchange
Ticker Symbol HYPE3
Full Company Profile

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.

Financial Statements

News

There is no news available yet.